Skip to main content
Retour
XENE logo

Xenon Pharmaceuticals Inc.

Qualité des données : 100%
XENE
NASDAQ Healthcare Biotechnology
53,38 €
▼ 1,04 € (-1,91%)
Cap. Boursière : 4,44B
Fourchette du Jour
52,55 € 54,19 €
Fourchette 52 Semaines
26,74 € 63,95 €
Volume
1 104 754
Moyenne 50J / 200J
45,08 € / 39,69 €
Clôture Précédente
54,42 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -12,8 0,3
P/B 7,6 2,9
ROE % -51,8 3,7
Net Margin % -4612,1 3,8
Rev Growth 5Y % -20,1 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
76,67 € +43.6%
Low: 44,00 € High: 100,00 €
BPA Prévisionnel
-4,80 €
CA Est.
4,4 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 5,26 €
-0,12 € – 14,65 €
1,3 B 5
FY2029 1,59 €
-0,04 € – 4,43 €
790 M 11
FY2028 -2,95 €
-5,82 € – 1,54 €
280 M 13

Points Clés

Revenue declined -20,14% annually over 5 years
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -279,92M

Croissance

Revenue Growth (5Y)
-20,14%
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-51,76%
ROIC-47,45%
Net Margin-4612,13%
Op. Margin-4974,27%

Sécurité

Debt / Equity
0,01
Current Ratio13,42
Interest Coverage0,00

Valorisation

P/E Ratio
-12,84
P/B Ratio7,63
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -20,14% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7,50M Net Income (TTM) -345,91M
ROE -51,76% ROA -35,24%
Gross Margin 66,09% Operating Margin -4974,27%
Net Margin -4612,13% Free Cash Flow (TTM) -279,92M
ROIC -47,45% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 13,42
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -12,84 P/B Ratio 7,63
P/S Ratio 592,09 PEG Ratio -0,23
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 4,44B Enterprise Value 4,25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7,50M 0,0 0,0 9,43M 18,44M
Net Income -345,91M -234,33M -182,39M -125,37M -78,88M
EPS (Diluted) -4,36 -3,01 -2,73 -2,06 -1,77
Gross Profit 4,96M -2,56M -167,51M 9,43M 18,44M
Operating Income -373,07M -279,30M -214,05M -129,14M -78,99M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 981,67M 798,14M 964,80M 754,15M 572,01M
Total Liabilities 399,91M 43,24M 36,88M 32,65M 21,97M
Shareholders' Equity 581,76M 754,90M 927,92M 721,50M 550,03M
Total Debt 7,94M 9,02M 10,90M 10,44M 8,26M
Cash & Equivalents 199,16M 142,71M 148,64M 57,24M 175,69M
Current Assets 560,65M 635,26M 644,96M 600,30M 559,02M
Current Liabilities 41,79M 35,59M 27,27M 22,70M 14,32M